Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P29466

UPID:
CASP1_HUMAN

ALTERNATIVE NAMES:
Interleukin-1 beta convertase; Interleukin-1 beta-converting enzyme; p45

ALTERNATIVE UPACC:
P29466; B5MDZ1; Q53EY6; Q6DMQ1; Q6GSS3; Q6PI75; Q9UCN3

BACKGROUND:
Caspase-1, recognized by alternative names such as Interleukin-1 beta-converting enzyme, is a thiol protease crucial for initiating inflammatory responses and pyroptosis by cleaving key proteins like IL1B, IL18, and GSDMD. Its activity is essential for the immune system's response to infection and stress, highlighting its role in cell immunity and inflammation. Caspase-1 also plays a role in antiviral immunity by inactivating CGAS during DNA virus challenges.

THERAPEUTIC SIGNIFICANCE:
The exploration of Caspase-1's functions offers promising avenues for developing new therapeutic approaches for inflammatory and infectious diseases. By targeting the mechanisms through which Caspase-1 regulates inflammation and cell death, researchers can potentially create innovative treatments that modulate the immune system's response to various pathological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.